Meridian Bioscience (VIVO) Tops Q3 EPS by 7c, Revenues Miss; Offers FY19 EPS Guidance

July 30, 2019 7:35 AM

Meridian Bioscience (NASDAQ: VIVO) reported Q3 EPS of $0.16, $0.07 better than the analyst estimate of $0.09. Revenue for the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found